A decision, likely to come in June, would be a major victory for the FDA’s authority to regulate prescription drugs and for abortion-rights advocates who have sought to protect access to mifepristone
Related posts:
A pricey new drug that may not work? Why drug pricing critics are staying quiet.
POLITICO-Harvard poll: Americans sharply divided over vaccine mandates
Biden’s vaccine charge hits a wall
Utah governor admits mistake on vaccination milestone
‘It’s a sore spot for a lot of people’: Why officials are raising questions about Biden’s vaccine donations
Texas, Florida see uptick in Obamacare enrollment
Senate panel advances Biden’s FDA pick in 13-8 vote
Health official on monkeypox: ‘I feel like this is a virus we understand’
Michigan groups ask state court to put abortion rights measure on the Nov. ballot
U.S. will divert travelers who have been to Uganda to 5 airports as Ebola outbreak worsens
Three years into the pandemic, nursing home residents are still in Covid’s crosshairs
New front opens in abortion wars as pharmacies begin dispensing pills
